

Edgar Filing: ZONAGEN INC - Form 8-K

ZONAGEN INC
Form 8-K
April 30, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): APRIL 29, 2002

ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

0-21198
(COMMISSION FILE NUMBER)

76-02
(I.R.S. EMPLOYER I

2408 TIMBERLOCH PLACE, SUITE B-4
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)

(281) 367-5892
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)

ITEM 5. OTHER EVENTS

On April 29, 2002, Zonagen, Inc. issued a press release announcing that it has been informed by the worldwide licensee of Vasomax(R) that the Marketing Authorization Application for Vasomax(R) in the United Kingdom will be withdrawn. This decision was made following a review of the comments received from the Committee on Safety of Medicines regarding the Vasomax(R) submission. Vasomax(R) is Zonagen's oral therapy for the treatment of erectile dysfunction.

The press release is filed as an exhibit to this Current Report on Form 8-K and is incorporated by reference herein.

ITEM 7. EXHIBITS

Exhibit 99.1 -- Press Release dated April 29, 2002.

SIGNATURES

Edgar Filing: ZONAGEN INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZONAGEN, INC.

Date: April 30, 2002.

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.

Vice President, Business Development
and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number -----	Description -----
99.1	Press Release dated April 29, 2002.